Jianhua Zhu

Dr. Jianhua Zhu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJing Luo
Jing Luo
JYJian-Feng Yao
Jian-Feng Yao
XDXiao-Fei Deng
Xiao-Fei Deng
XZXiao-Dan Zheng
Xiao-Dan Zheng
MJMin Jia
Min Jia
JZJianhua Zhu
Jianhua Zhu
14,15-epoxyeicosatrienoic acid (14,15-EET) is an important lipid signaling molecule involved in the regulation of tumor metastasis, however, the role and molecular mechanisms of 14,15-EET activity in breast cancer cell epithelial-mesenchymal transition (EMT) and drug resistance remain enigmatic. The 14, 15-EET level in serum and in tumor or non-cancerous tissue from breast cancer patients was measured by ELISA. qRT-PCR and western blot analyses were used to examine expression of integrin αvβ3. The role of 14, 15-EET in breast cancer cell adhesion, invasion was explored by adhesion and Transwell assays. The role of 14, 15-EET in breast cancer cell cisplatin resistance in vitro was determined by MTT assay. Western blot was conducted to detect the protein expressions of EMT-related markers and FAK/PI3K/AKT signaling. Xenograft models in nude mice were established to explore the roles of 14, 15-EET in breast cancer cells EMT and cisplatin resistance in vivo. In the present study, we show that serum level of 14, 15-EET increases in breast cancer patients and 14, 15-EET level of tumor tissue is higher than that of non-cancerous tissue. Moreover, 14, 15-EET increases integrin αvβ3 expression, leading to FAK activation. 14, 15-EET induces breast cancer cell EMT via integrin αvβ3 and FAK/PI3K/AKT cascade activation in vitro. Furthermore, we find that 14, 15-EET induces breast cancer cells EMT and cisplatin resistance in vivo, αvβ3 integrin and the resulting FAK/PI3K/AKT signaling pathway are responsible for 14, 15-EET induced-breast cancer cells cisplatin resistance. Our findings suggest that inhibition of 14, 15-EET or inactivation of integrin αvβ3/FAK/PI3K/AKT pathway could serve as a novel approach to reverse EMT and cisplatin resistance in breast cancer cells.

9 November 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HZHao Zhou
Hao Zhou
WLWei Liu
Wei Liu
YZYongming Zhou
Yongming Zhou
ZHZhenya Hong
Zhenya Hong
JNJian Ni
Jian Ni
JZJianhua Zhu
Jianhua Zhu
Background: Acute myeloid leukemia (AML) is the most common type of leukemia in adults. Its therapy has not significantly improved during the past four decades despite intense research efforts. New molecularly targeted therapies are in great need. The proto-oncogene c-Myc (MYC) is an attractive target due to its transactivation role in multiple signaling cascades. Deregulation of the MYC is considered one of a series of oncogenic events required for tumorigenesis. However, limited knowledge is available on which mechanism underlie MYC dysregulation and how long non-coding RNAs (lncRNAs) are involved in MYC dysregulation in AML. Methods: AML microarray chips and public datasets were screened to identify novel lncRNA GAS6-AS1 was dysregulated in AML. Gain or loss of functional leukemia cell models were produced, and in vitro and in vivo experiments were applied to demonstrate its leukemogenic phenotypes. Interactive network analyses were performed to define intrinsic mechanism. Results: We identified GAS6-AS1 was overexpressed in AML, and its aberrant function lead to more aggressive leukemia phenotypes and poorer survival outcomes. We revealed that GAS6-AS1 directly binds Y-box binding protein 1 (YBX1) to facilitate its interaction with MYC, leading to MYC transactivation and upregulation of IL1R1, RAB27B and other MYC target genes associated with leukemia progression. Further, lentiviral-based GAS6-AS1 silencing inhibited leukemia progression in vivo. Conclusions: Our findings revealed a previously unappreciated role of GAS6-AS1 as an oncogenic lncRNA in AML progression and prognostic prediction. Importantly, we demonstrated that therapeutic targeting of the GAS6-AS1/YBX1/MYC axis inhibits AML cellular propagation and disease progression. Our insight in lncRNA associated MYC-driven leukemogenesis may contribute to develop new anti-leukemia treatment strategies.

1 November 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JZJianhua Zhu
Jianhua Zhu
JLJing Luo
Jing Luo
YLYongchao Li
Yongchao Li
MJMin Jia
Min Jia
YWYueqin Wang
Yueqin Wang
SKShuhong Ke
Shuhong Ke

1 April 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JZJianhua Zhu
Jianhua Zhu
JYJianfeng Yao
Jianfeng Yao
RHRongfu Huang
Rongfu Huang
YWYueqin Wang
Yueqin Wang
MJMin Jia
Min Jia
YHYan Huang
Yan Huang

1 February 2021 in Life Sciences
Verified
Journal Article
Closed access
CHChunmei Huang
Chunmei Huang
KLKe Li
Ke Li
RHRongfu Huang
Rongfu Huang
JZJianhua Zhu
Jianhua Zhu
JYJiayao Yang
Jiayao Yang

1 April 2017 in Archives of Medical Research
Verified
Journal Article
Closed access
MJMin Jia
Min Jia
HYHuaning Yao
Huaning Yao
CCChao Chen
Chao Chen
YWYueqin Wang
Yueqin Wang
HWHan Wang
Han Wang
JZJianhua Zhu
Jianhua Zhu